Pipeline

Platform

ADC Program

Target

Indication

Discovery

Preclinical

P1 Dose
Escalation

P1 Dose
Expansion

Phase

Mersana’s innovative platforms have enabled us to build a pipeline for both Mersana and our collaborators. Our ADCs in preclinical studies and clinical trials are first-in-class molecules that target multiple tumor types with high unmet medical need.
We believe our platforms create an opportunity for ADCs with improved safety and efficacy relative to those developed using first-generation technology.

PlatformADC ProgramTargetIndicationDiscoveryPreclinicalP1 Dose EscalationP1 Dose Expansion
G1
Dolasynthen
XMT-1660
B7-H4 Multiple Solid Tumors
G2
Immunosynthen
XMT-2056*
Novel HER2 Epitope Multiple Solid Tumors
Immunosynthen
XMT-2068
Undisclosed Undisclosed
Immunosynthen
XMT-2175
Undisclosed Undisclosed
Collaborations
Collaborations:
Dolasynthen
Multiple Undisclosed
Immunosynthen
Multiple Undisclosed
Platform ADC Program Target Indication Phase
Dolasynthen XMT-1660 B7-H4 Multiple Solid Tumors P1 Dose Escalation
Immunosynthen XMT-2056* Novel HER2 Epitope Multiple Solid Tumors P1 Dose Escalation
XMT-2068 Undisclosed Undisclosed Discovery
XMT-2175 Undisclosed Undisclosed Discovery
Collaborators:
Immunosynthen Janssen Logo Multiple Undisclosed Discovery
Dolasynthen Janssen Logo Multiple Undisclosed Discovery

Additional collaboration with Asana Biosciences focusing on one product candidate developed utilizing Dolaflexin, Mersana’s first-generation ADC platform.

*XMT-2056 is wholly owned by Mersana, with GSK having an exclusive global license option to co-develop and commercialize the candidate.